Outbreak of metabolic dysfunction-associated steatohepatitis pharmacotherapies in 2024: From resmetirom to tirzepatide.
10.1097/CM9.0000000000003417
- Author:
Rui HUANG
1
;
Chunli ZHANG
2
;
Xiaodong MO
3
;
Huiying RAO
1
Author Information
1. Peking University People's Hospital, Peking University Hepatology Institute, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Beijing 100044, China.
2. Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
3. Peking University People's Hospital, Department of Hematology, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China.
- Publication Type:Journal Article
- From:
Chinese Medical Journal
2025;138(2):127-129
- CountryChina
- Language:English